Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 15, 2021
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
000-52138
20-2000871
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
100 – 740 McCurdy Road, Kelowna, BC Canada
V1X 2P7
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (250) 765-6424
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on
which registered
Common Stock, par value $0.001 per share
Warrants to Purchase Common Stock
LEXX
LEXXW
The Nasdaq Capital Market
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
Regulation FD Disclosure
On June 15, 2021, Lexaria Bioscience Corp. announced the positive results regarding its tolerability and pharmacokinetic animal study, VIRAL-A20-2 (the “Study”) which evaluated DehydraTECH-enabled remdesivir and ebastine. The Study identified levels of remdesivir and ebastine in the bloodstream of male Sprague-Dawley rats at rates of two to three times higher with DehydraTECH than without, thus providing potential opportunities for the treatment of viral infections via oral drug delivery rather than injections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
/s/ Chris Bunka
Chris Bunka
CEO, Principal Executive Officer
Date: June 16, 2021
- 3 -
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
